Investor Presentation
24.
Investor presentation First six months of 2022
Sales growth of 16%, driven by the GLP-1 portfolio for diabetes
and obesity treatment
Novo NordiskⓇ
Novo Nordisk reported quarterly sales
DKK
billion
50
by therapy
Reported sales
CAGR¹: 8.0%
40
40
Reported sales for the first six
months of 2022
Rare Other
Rare endocrine rare
blood disorders disease
Reported sales and growth breakdown for
the first six months of 2022
Therapy
Sales
(mDKK)
Share of
Growth
growth
Total GLP-12
36,651
45%
96%
Long-acting insulin³
8,900
-6%
-5%
disorders
Premix insulin4
1%
5,513
-8%
-4%
-4.7%¹
5%
Fast-acting insulin5
8.729
-6%
-5%
Obesity
7%
30
Human insulin
4,163
-15%
-6%
2.8%1
care
8%
Total insulin
27,305
-8%
-21%
2.9%1
Other Diabetes care
1,714
-16%
-3%
20
8.8%¹
Total Diabetes care
Obesity care7
65,670
15%
72%
7,045
84%
27%
10
79%
Diabetes care
Diabetes and Obesity care
Rare blood disorders
72,715
19%
100%
5,940
3%
2%
0
Q2
2012
Other rare disease
Rare endocrine disorders
Rare blood disorders
Q2
2022
Rare endocrine disorders
Other Rare disease 10
Rare disease
3,743
-5%
-2%
898
7%
1%
10,581
0%
0%
Diabetes and Obesity care
Sales of DKK 83.3 billion
(+25%)
Total
83,296
16%
100%
Source: Quarterly company announcement
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®, Rybelsus®; 3 Comprises TresibaⓇ, XultophyⓇ and Levemir®; 4 Comprises RyzodegⓇ and Novo MixⓇ; 5 Comprises FiaspⓇ and NovoRapidⓇ; 6 Primarily NovonormⓇ, needles and GlucaGen® HypoKitⓇ;
7 Comprises SaxendaⓇ and Wegovy®: 8 Comprises NovoSeven®, Novo Eight®, NovoThirteen®, Refixia®, and EsperoctⓇ: 9 Comprises Norditropin and Macrilen TM; 10 Primarily Vagifem® and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 24%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation